REG - Hutchmed China Ltd - Annual General Meeting Poll Results

HUTCHMED (China)Announcement

27/04/2022 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220427:nRSa5742Ja&default-theme=true

RNS Number : 5742J  Hutchmed (China) Limited  27 April 2022

 

 

Annual General Meeting held on April 27, 2022 - Poll Results

 

 

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 27, 2022:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the
"Company") (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary
resolutions and special resolution put to its Annual General Meeting ("AGM")
held on April 27, 2022 were duly passed.  The poll results of the resolutions
were as follows:

 

 

                                                                                              Number of Votes (%)*

                                                                                                                                     Passed by Shareholders

 Ordinary Resolutions

              For                                                                             Against      Withheld(#)

 1.           To consider and adopt the audited financial statements, and the reports of the  686,224,906  2,960         7,697,445   Yes
              directors and independent auditors for the year ended December 31, 2021.

                                                                               (99.9996%)   (0.0004%)

 2(A).        To re-elect Mr TO Chi Keung, Simon as a director.                               635,955,913  51,971,563    5,997,835   Yes

                                                                                              (92.4452%)   (7.5548%)

 2(B).        To re-elect Dr Weiguo SU as a director.                                         686,123,331  1,804,145     5,997,835   Yes

                                                                                              (99.7377%)   (0.2623%)

 2(C).        To re-elect Mr CHENG Chig Fung, Johnny as a director.                           685,947,446  1,980,030     5,997,835   Yes

                                                                                              (99.7122%)   (0.2878%)

 2(D).        To re-elect Dr Dan ELDAR as a director.                                         684,647,400  3,280,076     5,997,835   Yes

                                                                                              (99.5232%)   (0.4768%)

 2(E).        To re-elect Ms Edith SHIH as a director.                                        681,250,085  6,677,146     5,998,080   Yes

                                                                                              (99.0294%)   (0.9706%)

 2(F).        To re-elect Mr Paul Rutherford CARTER as a director.                            686,252,741  1,674,735     5,997,835   Yes

                                                                                              (99.7566%)   (0.2434%)

 2(G).        To re-elect Dr Karen Jean FERRANTE as a director.                               687,778,031  149,445       5,997,835   Yes

                                                                                              (99.9783%)   (0.0217%)

 2(H).        To re-elect Mr Graeme Allan JACK as a director.                                 674,126,615  12,957,617    6,841,079   Yes

                                                                                              (98.1141%)   (1.8859%)

 2(I).        To re-elect Professor MOK Shu Kam, Tony as a director.                          670,413,452  17,501,649    6,010,210   Yes

                                                                                              (97.4558%)   (2.5442%)

 3.           To appoint PricewaterhouseCoopers and                                           685,514,922  8,392,264     18,125      Yes
              PricewaterhouseCoopers Zhong Tian LLP as the auditors of the Company for Hong

              Kong financial reporting and U.S. financial reporting purposes, respectively,   (98.7906%)   (1.2094%)
              and to authorize the Directors to fix the auditors' remuneration.

 Special Resolution
 4.           To grant a general mandate to the directors of the Company to issue additional  683,701,055  4,221,351     6,002,905   Yes

            shares.^

                                                                               (99.3864%)   (0.6136%)

 Ordinary Resolutions
 5(1).        To grant a general mandate to the directors of the Company to repurchase        687,914,356  7,770         6,003,185   Yes
              shares of the Company.^

                                                                               (99.9989%)   (0.0011%)

 5(2).        To refresh the scheme mandate limit under the Long Term Incentive Plan.^        601,082,095  53,973,751    38,869,465  Yes

                                                                                              (91.7604%)   (8.2396%)

 

*  Percentages rounded to 4 decimal places

(#) A vote withheld is not a vote in law and is not counted in the calculation
of the proportion of the votes for and against a resolution.

^ The full text of Resolutions 4 and 5 are set out in the Notice of AGM.

 

All directors of the Company, namely Mr TO Chi Keung, Simon, Dr Weiguo SU, Mr
CHENG Chig Fung, Johnny, Dr Dan ELDAR, Ms Edith SHIH, Mr Paul Rutherford
CARTER, Dr Karen Jean FERRANTE, Mr Graeme Allan JACK and Professor MOK Shu
Kam, Tony, attended the AGM, either in person or by means of electronic
facilities.

 

Notes:

 

(1)     Number of shares entitling the holders to attend and vote on all
the resolutions at the AGM: 864,530,850 shares.

 

(2)    Number of shares entitling the holders to attend and abstain from
voting in favour as set out in Rule 13.40 of the Rules Governing the Listing
of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")
at the AGM: Nil.

 

(3)     Number of shares for holders required under the Listing Rules to
abstain from voting at the AGM: Nil.

 

(4)    The scrutineer for the poll at the AGM was Computershare Investor
Services (Jersey) Limited, the Principal Share Registrar of the Company.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 4,600
personnel across all its companies, at the center of which is a team of about
1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug
candidates from in-house discovery into clinical studies around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS
 Investor Enquiries
 Mark Lee, Senior Vice President    +852 2121 8200
 Annie Cheng, Vice President        +1 (973) 567 3786

 Media Enquiries
 Americas - Brad Miles,             +1 (917) 570 7340 (Mobile)

bmiles@troutgroup.com (mailto:bmiles@troutgroup.com)
 Solebury Trout
 Europe - Ben Atwell / Alex Shaw,   +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

                                  +44 7779 545 055 (Mobile)
 FTI Consulting

                                    HUTCHMED@fticonsulting.com (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi,                    +852 9783 6894 (Mobile)

HUTCHMED@brunswickgroup.com (mailto:HUTCHMED@brunswickgroup.com)
 Brunswick

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,  +44 (20) 7886 2500

 Panmure Gordon (UK) Limited

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFLFLVSDIDFIF